forced expiratory volume

Summary

Summary: Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity.

Top Publications

  1. ncbi The nature of small-airway obstruction in chronic obstructive pulmonary disease
    James C Hogg
    University of British Columbia, the Centre for Cardiovascular and Pulmonary Research, and St Paul s Hospital, Vancouver, Canada
    N Engl J Med 350:2645-53. 2004
  2. ncbi The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease
    Bartolome R Celli
    COPD Center at St Elizabeth s Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA
    N Engl J Med 350:1005-12. 2004
  3. ncbi A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    Donald P Tashkin
    David Geffen School of Medicine at the University of California, Los Angeles 90095 1690, USA
    N Engl J Med 359:1543-54. 2008
  4. pmc Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
    G C Donaldson
    Academic Unit of Respiratory Medicine, St Bartholomew s and Royal London School of Medicine and Dentistry, UK
    Thorax 57:847-52. 2002
  5. pmc Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
    J J Soler-Cataluña
    Unidad de Neumología, Servicio de Medicina Interna, Hospital General de Requena, Paraje Casablanca s n 46340, Requena Valencia, Spain
    Thorax 60:925-31. 2005
  6. ncbi Changes in forced expiratory volume in 1 second over time in COPD
    Jørgen Vestbo
    Respiratory Section, Hvidovre Hospital, Hvidovre, Denmark
    N Engl J Med 365:1184-92. 2011
  7. pmc Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis
    W Q Gan
    The James Hogg iCAPTURE Center for Cardiovascular and Pulmonary Research, St Paul s Hospital, Room 368A, 1081 Burrard Street, Vancouver, British Columbia, Canada V6A 1Y6
    Thorax 59:574-80. 2004
  8. ncbi Chronic obstructive pulmonary disease phenotypes: the future of COPD
    MeiLan K Han
    University of Michigan Pulmonary and Critical Care, 1500 E Medical Center Drive, 3916 Taubman, Ann Arbor, MI 48109, USA
    Am J Respir Crit Care Med 182:598-604. 2010
  9. ncbi Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
    James F Donohue
    University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
    Am J Respir Crit Care Med 182:155-62. 2010
  10. pmc Genome-wide association study identifies five loci associated with lung function
    Emmanouela Repapi
    Departments of Health Sciences and Genetics, Adrian Building, University of Leicester, Leicester, UK
    Nat Genet 42:36-44. 2010

Detail Information

Publications271 found, 100 shown here

  1. ncbi The nature of small-airway obstruction in chronic obstructive pulmonary disease
    James C Hogg
    University of British Columbia, the Centre for Cardiovascular and Pulmonary Research, and St Paul s Hospital, Vancouver, Canada
    N Engl J Med 350:2645-53. 2004
    ..We examined the evolution of the pathological effects of airway obstruction in patients with COPD...
  2. ncbi The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease
    Bartolome R Celli
    COPD Center at St Elizabeth s Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA
    N Engl J Med 350:1005-12. 2004
    ..A physiological variable--the forced expiratory volume in one second (FEV1)--is often used to grade the severity of COPD...
  3. ncbi A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    Donald P Tashkin
    David Geffen School of Medicine at the University of California, Los Angeles 90095 1690, USA
    N Engl J Med 359:1543-54. 2008
    ..Previous studies showing that tiotropium improves multiple end points in patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term effects of tiotropium therapy...
  4. pmc Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
    G C Donaldson
    Academic Unit of Respiratory Medicine, St Bartholomew s and Royal London School of Medicine and Dentistry, UK
    Thorax 57:847-52. 2002
    ..The aim of this study was to investigate whether these are related...
  5. pmc Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
    J J Soler-Cataluña
    Unidad de Neumología, Servicio de Medicina Interna, Hospital General de Requena, Paraje Casablanca s n 46340, Requena Valencia, Spain
    Thorax 60:925-31. 2005
    ..However, little is known about the prognostic consequences of these exacerbations. A study was undertaken to investigate whether severe acute exacerbations of COPD exert a direct effect on mortality...
  6. ncbi Changes in forced expiratory volume in 1 second over time in COPD
    Jørgen Vestbo
    Respiratory Section, Hvidovre Hospital, Hvidovre, Denmark
    N Engl J Med 365:1184-92. 2011
    A key feature of chronic obstructive pulmonary disease (COPD) is an accelerated rate of decline in forced expiratory volume in 1 second (FEV(1)), but data on the variability and determinants of this change in patients who have established ..
  7. pmc Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis
    W Q Gan
    The James Hogg iCAPTURE Center for Cardiovascular and Pulmonary Research, St Paul s Hospital, Room 368A, 1081 Burrard Street, Vancouver, British Columbia, Canada V6A 1Y6
    Thorax 59:574-80. 2004
    ..Systemic inflammation may be involved in the pathogenesis of these disorders. A study was undertaken to determine whether systemic inflammation is present in stable COPD...
  8. ncbi Chronic obstructive pulmonary disease phenotypes: the future of COPD
    MeiLan K Han
    University of Michigan Pulmonary and Critical Care, 1500 E Medical Center Drive, 3916 Taubman, Ann Arbor, MI 48109, USA
    Am J Respir Crit Care Med 182:598-604. 2010
    ..We have much yet to learn, but establishing a common language for future research will facilitate our understanding and management of the complexity implicit to this disease...
  9. ncbi Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
    James F Donohue
    University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
    Am J Respir Crit Care Med 182:155-62. 2010
    ..Indacaterol is the first once-daily, long-acting inhaled beta(2)-agonist bronchodilator studied in patients with chronic obstructive pulmonary disease (COPD)...
  10. pmc Genome-wide association study identifies five loci associated with lung function
    Emmanouela Repapi
    Departments of Health Sciences and Genetics, Adrian Building, University of Leicester, Leicester, UK
    Nat Genet 42:36-44. 2010
    ..We tested genome-wide association with forced expiratory volume in 1 s (FEV(1)) and the ratio of FEV(1) to forced vital capacity (FVC) in the SpiroMeta consortium (n = ..
  11. pmc Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function
    Dana B Hancock
    Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina, USA
    Nat Genet 42:45-52. 2010
    ..We meta-analyzed genome-wide association studies for two clinically important lung-function measures: forced expiratory volume in the first second (FEV(1)) and its ratio to forced vital capacity (FEV(1)/FVC), an indicator of airflow ..
  12. ncbi Properties of the COPD assessment test in a cross-sectional European study
    P W Jones
    Division of Clinical Science, St George s University of London, Cranmer Terrace, London SW17 0RE, UK
    Eur Respir J 38:29-35. 2011
    ..8, p<0.0001). The CAT is a simple and easy-to-use questionnaire that distinguishes between patients of different degrees of COPD severity and appears to behave the same way across countries...
  13. ncbi Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD
    Ronald Dahl
    Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
    Thorax 65:473-9. 2010
    ..In previous studies, indacaterol provided 24 h bronchodilation on once-daily dosing with a fast onset of action. This study compared the efficacy and safety of indacaterol with the twice-daily LABA formoterol and placebo over 1 year...
  14. ncbi Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society
    Amir Qaseem
    American College of Physicians and Temple University, Philadelphia, Pennsylvania 19106, USA
    Ann Intern Med 155:179-91. 2011
    ....
  15. ncbi Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial
    Marc Decramer
    Respiratory Division, University of Leuven, Leuven, Belgium
    Lancet 374:1171-8. 2009
    ..However, there are few data for treatment in the early stages of the disease. We examined the effect of tiotropium on outcomes in a large subgroup of patients with moderate COPD...
  16. ncbi High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial
    An Lehouck
    University Hospitals Leuven, Belgium
    Ann Intern Med 156:105-14. 2012
    ..Because many patients with chronic obstructive pulmonary disease (COPD) have vitamin D deficiency, effects of vitamin D supplementation may extend beyond preventing osteoporosis...
  17. ncbi Airway and systemic inflammation and decline in lung function in patients with COPD
    Gavin C Donaldson
    Academic Unit of Respiratory Medicine, St Bartholomew s and Royal London Hospital School of Medicine and Dentistry, London, UK
    Chest 128:1995-2004. 2005
    ..Patients with COPD experience lower airway and systemic inflammation, and an accelerated decline in FEV1. There is no evidence on whether this inflammation changes over time, or if it is associated with a faster decline in FEV1...
  18. ncbi Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease
    Masaharu Nishimura
    First Department of Medicine, Hokkaido University School of Medicine, and Center for Respiratory Diseases, Hokkaido Social Insurance Hospital, N 15 W 7, Kita ku, Sapporo 060 8638, Japan
    Am J Respir Crit Care Med 185:44-52. 2012
    ..Although the rate of annual decline in FEV1 is one of the most important outcome measures in chronic obstructive pulmonary disease (COPD), little is known about intersubject variability based on clinical phenotypes...
  19. pmc Physical inactivity in patients with COPD, a controlled multi-center pilot-study
    Thierry Troosters
    Pulmonary Rehabilitation and Respiratory Division, UZ Gasthuisberg, Leuven, Belgium
    Respir Med 104:1005-11. 2010
    ..Studies in moderate COPD are currently scarce. The aim of the present study was to investigate physical activity in daily life in patients with COPD (n=70) and controls (n=30)...
  20. ncbi Forced vital capacity, airway obstruction and survival in a general population sample from the USA
    P G J Burney
    National Heart Lung Institute, Imperial College, London, UK
    Thorax 66:49-54. 2011
    Many studies show a link between forced expiratory volume in 1 s (FEV(1)) and survival in the general population and this has been interpreted as a link between airway obstruction and survival...
  21. pmc Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids
    R H Green
    Institute for Lung Health, Department of Respiratory Medicine and Thoracic Surgery, Glenfield Hospital, Groby Road, Leicester LE3 9PQ, UK
    Thorax 57:875-9. 2002
    ....
  22. ncbi Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)
    J Vestbo
    Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    Eur Respir J 31:869-73. 2008
    Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease and not well understood. The forced expiratory volume in one second is used for the diagnosis and staging of COPD, but there is wide acceptance that it is a crude ..
  23. pmc Developing COPD: a 25 year follow up study of the general population
    A Løkke
    Department of Cardiology and Respiratory Medicine, 253 Hvidovre Hospital, Kettegard Alle 30, DK 2650 Hvidovre, Denmark
    Thorax 61:935-9. 2006
    ..The aim of this study was to determine the 25 year absolute risk of developing COPD in men and women from the general population...
  24. pmc Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations
    I S Patel
    Academic Respiratory Medicine, St Bartholomew s and Royal London School of Medicine and Dentistry, London EC1A 7BE, UK
    Thorax 57:759-64. 2002
    ..Stable COPD patients often have lower airway bacterial colonisation which may be an important stimulus to airway inflammation and thereby modulate exacerbation frequency...
  25. ncbi The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort
    Ciro Casanova
    Pulmonary Department, Hospital Universitario La Candelaria, Tenerife, Spain
    Am J Respir Crit Care Med 184:1015-21. 2011
    ..Chronic obstructive pulmonary disease (COPD) is thought to result in rapid and progressive loss of lung function usually expressed as mean values for whole cohorts...
  26. ncbi Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD
    Koichi Nishimura
    Respiratory Division, Kyoto Katsura Hospital, Kyoto, Japan
    Chest 121:1434-40. 2002
    ....
  27. ncbi Effect of indacaterol on exercise endurance and lung hyperinflation in COPD
    Denis E O'Donnell
    Queen s University and Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada
    Respir Med 105:1030-6. 2011
    ..This study investigated the effect of indacaterol on exercise endurance, and on lung hyperinflation during exercise and at rest in patients with moderate-to-severe COPD...
  28. ncbi Mortality after hospitalization for COPD
    Pedro Almagro
    Internal Medicine, Hospital Mutua de Terrassa, University of Barcelona, Barcelona, Spain
    Chest 121:1441-8. 2002
    ..To identify variables associated with mortality in patients admitted to the hospital for acute exacerbation of COPD...
  29. pmc Risk factors of readmission to hospital for a COPD exacerbation: a prospective study
    J Garcia-Aymerich
    Respiratory and Environmental Health Research Unit, IMIM, Barcelona, Spain
    Thorax 58:100-5. 2003
    ..The association between readmission for a COPD exacerbation and a wide range of modifiable potential risk factors, after adjusting for sociodemographic and clinical factors, has been assessed...
  30. ncbi Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels
    J A Wedzicha
    Department of Academic Respiratory Medicine, St Bartholomew s and Royal London School of Medicine and Dentistry, Queen Mary and Westfield College, London, UK
    Thromb Haemost 84:210-5. 2000
    ....
  31. ncbi Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study
    Bartolome R Celli
    Tufts University School of Medicine, Pulmonary and Critical Care Division, Caritas St Elizabeth s Medical Center, Boston, MA 02135 2997, USA
    Am J Respir Crit Care Med 178:332-8. 2008
    ..Chronic obstructive pulmonary disease (COPD) is characterized by an accelerated decline in lung function. No drug has been shown conclusively to reduce this decline...
  32. ncbi Predictors of success and failure in pulmonary rehabilitation
    R Garrod
    School of Physiotherapy, Faculty of Health and Social Care Sciences, St George s, University of London, UK
    Eur Respir J 27:788-94. 2006
    ..mean+/-sd age 68+/-10 yrs), 21 MRC dyspnoea score grade 1/2, 29 grade 3/4 and 24 grade 5, with a mean forced expiratory volume in one second of 1.1+/-0.6 L, attended for rehabilitation...
  33. pmc Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
    Christine R Jenkins
    Woolcock Institute of Medical Research, Sydney, Australia
    Respir Res 10:59. 2009
    ..However, there are only limited data about the influence of GOLD severity staging on the effectiveness of SFC, particularly in patients with milder disease...
  34. ncbi TLR4 mutations are associated with endotoxin hyporesponsiveness in humans
    N C Arbour
    1 Department of Medicine, Department of Veterans Affairs Medical Center, The University of Iowa, Iowa City, Iowa, USA
    Nat Genet 25:187-91. 2000
    ....
  35. pmc Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study
    Bushra Naveed
    Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA
    Am J Respir Crit Care Med 185:392-9. 2012
    ..Cross-sectional studies demonstrate an association between metabolic syndrome and impaired lung function...
  36. pmc MMP12, lung function, and COPD in high-risk populations
    Gary M Hunninghake
    Channing Laboratory and Center for Genomic Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 361:2599-608. 2009
    ..Genetic variants influencing lung function in children and adults may ultimately lead to the development of chronic obstructive pulmonary disease (COPD), particularly in high-risk groups...
  37. ncbi Minimal clinically important differences in COPD lung function
    James F Donohue
    Division of Pulmonary Diseases and Critical Care Medicine, School of Medicine, University of North Carolina at Chapel Hill, CB 7020, 4125 Bioinformatics Building, Chapel Hill, North Carolina 27599 7020, USA
    COPD 2:111-24. 2005
    ..Also distributional/statistical methods may be useful in determining the MCID FEV1...
  38. ncbi Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies
    Edward M Kerwin
    Clinical Research Institute of Southern Oregon PC, Medford, Oregon 97504, USA
    Clin Ther 33:1974-84. 2011
    ....
  39. ncbi Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial
    William W Busse
    Department of Medicine, University of Wisconsin, K4 910 CSC, 600 Highland Avenue, Madison, WI 53792, USA
    Thorax 67:35-41. 2012
    ..FF is being developed as a once-daily treatment in combination with the long-acting β(2) agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disease...
  40. ncbi Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients
    R M Mroz
    Department of Lung Diseases, Medical University of Bialystok, Zurawia 14, Bialystok, Poland
    Adv Exp Med Biol 756:23-8. 2013
    ..The patients' quality of life also changed favorably in the indacaterol treatment arm. We conclude that the add-on therapy with indacaterol exerts positive effects in COPD patients...
  41. ncbi Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index
    Milo A Puhan
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Lancet 374:704-11. 2009
    ..We assessed the calibration of the BODE index, updated it to improve its calibration, and developed and validated a simplified index for use in primary-care settings...
  42. ncbi Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study
    Claus Vogelmeier
    Klinik für Innere Medizin mit Schwerpunkt Pneumologie, Universitätsklinikum Giessen und Marburg, Standort Marburg Baldingerstrasse, D 35043 Marburg, Germany
    Respir Med 102:1511-20. 2008
    ..Combined bronchodilator therapy may be a valuable treatment option for patients with COPD...
  43. ncbi Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD
    Kai Michael Beeh
    insaf Respiratory Research Institute, D 65187 Wiesbaden, Germany
    COPD 8:340-5. 2011
    ..Patients (40-80 years) with post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) < 70%, percent predicted FEV1 ≥ 40% and ≤ 80%, smoking ..
  44. ncbi Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
    Peter M A Calverley
    School of Clinical Sciences, Liverpool, UK
    Lancet 374:685-94. 2009
    ..We therefore investigated whether roflumilast would reduce the frequency of exacerbations requiring corticosteroids in patients with COPD...
  45. ncbi QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Thorax 65:1086-91. 2010
    ....
  46. ncbi Prevalence, severity and underdiagnosis of COPD in the primary care setting
    M Bednarek
    2nd Department of Respiratory Medicine, National Research Institute of Tuberculosis and Lung Diseases, 26 Plocka St, Warsaw 01 138, Poland
    Thorax 63:402-7. 2008
    ..Chronic obstructive pulmonary disease (COPD) is a common disease with a steadily increasing prevalence and mortality. However, recent epidemiological estimates differ depending on the population studied and methods used...
  47. pmc Profiling serum biomarkers in patients with COPD: associations with clinical parameters
    Victor Pinto-Plata
    Caritas St Elizabeth s Medical Center, 736 Cambridge Street, Boston, Massachusetts 02135, USA
    Thorax 62:595-601. 2007
    ..A systematic analysis was undertaken of multiple protein analytes in the serum of well characterised patients with COPD and matched controls using novel protein microarray platform (PMP) technology...
  48. ncbi Are patients with COPD more active after pulmonary rehabilitation?
    Fabio Pitta
    Respiratory Rehabilitation and Respiratory Division, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Chest 134:273-80. 2008
    ..Despite a variety of benefits brought by pulmonary rehabilitation to patients with COPD, it is unclear whether these patients are more active during daily life after the program...
  49. ncbi Impact of preventing exacerbations on deterioration of health status in COPD
    S Spencer
    Dept of Health and Social Care, Brunel University, Isleworth, UK
    Eur Respir J 23:698-702. 2004
    ..0003). Exacerbation frequency and rate of decline in forced expiratory volume in one second were independently related to the rate of deterioration in SGRQ score...
  50. ncbi Inflammatory changes, recovery and recurrence at COPD exacerbation
    W R Perera
    Academic Unit of Respiratory Medicine, Royal Free and University College Medical School, Rowland Hill Street, Hampstead, London, NW3 2PF, UK
    Eur Respir J 29:527-34. 2007
    ..A high serum C-reactive protein concentration 14 days after an index exacerbation may be used as a predictor of recurrent exacerbations within 50 days...
  51. ncbi Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study
    Stephanie Korn
    Pulmonary Department, Mainz University Hospital, Mainz, Germany
    Respir Med 105:719-26. 2011
    ..Indacaterol is a novel, inhaled once-daily ultra-long-acting β(2)-agonist for the treatment of COPD...
  52. ncbi Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease
    Tobias Welte
    Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
    Am J Respir Crit Care Med 180:741-50. 2009
    ..Budesonide/formoterol and tiotropium are commonly used maintenance treatments for patients with chronic obstructive pulmonary disease. Combining these medications may provide additional benefits...
  53. ncbi Screening for and early detection of chronic obstructive pulmonary disease
    Joan B Soriano
    CIMERA International Center for Advanced Respiratory Medicine, Recinte Hospital Joan March, Bunyola, Spain
    Lancet 374:721-32. 2009
    ..All in all, spirometry is recognised as the essential test for diagnosis and monitoring of COPD...
  54. pmc A genome-wide association study of pulmonary function measures in the Framingham Heart Study
    Jemma B Wilk
    Department of Neurology, Boston University School of Medicine, Boston, MA, USA
    PLoS Genet 5:e1000429. 2009
    The ratio of forced expiratory volume in one second to forced vital capacity (FEV(1)/FVC) is a measure used to diagnose airflow obstruction and is highly heritable...
  55. pmc Overdiagnosis of asthma in obese and nonobese adults
    Shawn D Aaron
    Ottawa Health Research Institute, Ottawa, Ont, USA
    CMAJ 179:1121-31. 2008
    ..It is unclear whether asthma is overdiagnosed in developed countries, particularly among obese individuals, who may be more likely than nonobese people to experience dyspnea...
  56. pmc Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study
    Yoko Shibata
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan
    Int J Med Sci 8:514-22. 2011
    ..The relationship between the prevalence of AF and pulmonary function is unclear. The aim of this study was to evaluate this relationship in participants in a health check...
  57. ncbi Impact of cigarette smoking on maximal expiratory flows in a general population: the Takahata study
    Takako Nemoto
    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Japan
    Intern Med 50:2547-55. 2011
    ..The aim of this study was to evaluate the impact of cigarette smoking on MEFs in a general population, and to assess the validity of using this index to evaluate injury to the small airways...
  58. ncbi Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study
    P D Scanlon
    Division of Pulmonary and Critical Care Medicine, Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Respir Crit Care Med 161:381-90. 2000
    ..Respiratory symptoms were not predictive of changes in lung function. Smokers with airflow obstruction benefit from quitting despite previous heavy smoking, advanced age, poor baseline lung function, or airway hyperresponsiveness...
  59. ncbi Short term and long term effects of pulmonary rehabilitation on physical activity in COPD
    Claire Egan
    Department of Respiratory Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland
    Respir Med 106:1671-9. 2012
    ..The hypothesis of this study was that pulmonary rehabilitation would lead to a sustained increase in standard outcome measures and in daily physical activity...
  60. pmc Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches
    Didier Renard
    Novartis Pharma AG, Basel, Switzerland
    Respir Res 12:54. 2011
    ..The large inter-patient and inter-study variability in forced expiratory volume in 1 second (FEV1) with bronchodilators makes determination of optimal doses difficult in conventional ..
  61. ncbi Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial
    Richard Sterling
    Carolina Research, Respiratory Medicine, Orangeburg, SC 29118 2040, USA
    Respir Med 106:1110-5. 2012
    ..The aim of this study was to evaluate the efficacy of three once-daily doses and one twice-daily dose of VI used concurrently with ICS in adult patients (≥18 years) with persistent asthma. Safety was also assessed...
  62. ncbi Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers
    J A Hardie
    Institute of Internal Medicine, Deaconess Hospital, University of Bergen, Norway
    Eur Respir J 20:1117-22. 2002
    ..Obstructive Lung Disease (GOLD) has defined stage I chronic obstructive pulmonary disease (COPD) as forced expiratory volume in one second/forced vital capacity (FEV1/FVC)% <70% and a FEV1% predicted of >80%...
  63. ncbi Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
    ..The combination of short-acting beta(2)-agonists and anticholinergics in the treatment of COPD has been well documented, but data on combination of long-acting agents are lacking...
  64. ncbi The effects of body mass index on lung volumes
    Richard L Jones
    Pulmonary Division, University of Alberta, Edmonton, AB, Canada T6G 2B7
    Chest 130:827-33. 2006
    ..It is well known that obesity causes decreases in lung volumes, but there has never been a large study showing the correlation between body mass index (BMI) and the various lung volumes...
  65. ncbi Predictive accuracy of patient-reported exacerbation frequency in COPD
    J K Quint
    Academic Unit of Respiratory Medicine, University College London, Rowland Hill Street, London, NW3 2PF, UK
    Eur Respir J 37:501-7. 2011
    ..A total of 267 patients (forced expiratory volume in 1 s 1.14 L) recorded worsening of respiratory symptoms on daily diary cards for 1 yr...
  66. pmc Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease
    Elisabeth B Swallow
    Respiratory Muscle Laboratory, Royal Brompton Hospital, Fulham Road, London SW3 6NP, UK
    Thorax 62:115-20. 2007
    ..Prognosis in chronic obstructive pulmonary disease (COPD) is poorly predicted by indices of air flow obstruction, because other factors that reflect the systemic nature of the disease also influence prognosis...
  67. ncbi Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease
    Yusheng Qiu
    Lung Pathology, Department of Gene Therapy, Imperial College, Royal Brompton Hospital, London, United Kingdom
    Am J Respir Crit Care Med 168:968-75. 2003
    ..Thus, in COPD, in addition to CXCL8 and CXCR1, CXCL5 and CXCR2 appear to play important roles in the airway neutrophilia characteristic of severe exacerbations...
  68. pmc Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD
    R A O'Donnell
    Respiratory Cell and Molecular Biology, Division of Infection, Inflammation and Repair, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
    Thorax 59:837-42. 2004
    ..A number of research tools have been combined to study smokers with a range of COPD severities classified according to the GOLD criteria...
  69. ncbi Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD)
    H Takizawa
    Department of Laboratory Medicine and Respiratory Medicine, Tokyo University, School of Medicine, 7 3 1Hongo, Bunkyo ku, Tokyo 113, Japan
    Am J Respir Crit Care Med 163:1476-83. 2001
    ..Our study showed a close link between smoking and expression of TGF-beta1 in small airways. Our results also suggested that small airway epithelial cells might be involved in obstructive changes found in smokers and patients with COPD...
  70. ncbi The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort
    Robab Kohansal
    Epidemiology and Clinical Research, Fundación Caubet CIMERA Illes Balears, Recinte Hospital Joan March, 07110 Bunyola, Illes Balears, Spain
    Am J Respir Crit Care Med 180:3-10. 2009
    ..Understanding normal lung development and aging in health and disease, both in men and in women, is essential to interpreting any therapeutic intervention...
  71. pmc Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study
    John M Brehm
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, Mass, USA
    J Allergy Clin Immunol 126:52-8.e5. 2010
    ..Vitamin D status might play a role in preventing asthma exacerbations...
  72. ncbi Pulmonary function and abdominal adiposity in the general population
    Heather M Ochs-Balcom
    INFORMA, National Cancer Institute Regina Elena, Rome, Via Elio Chianesi 53, 00144 Rome, Italy
    Chest 129:853-62. 2006
    ..The mechanism for this association and the best marker of abdominal adiposity in relation to pulmonary function is not known...
  73. ncbi Systemic inflammation and COPD: the Framingham Heart Study
    Robert E Walter
    Section of Pulmonary, Allergy, and Critical Care Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Chest 133:19-25. 2008
    ..We examined the hypothesis that systemic inflammatory biomarkers are associated with impaired lung function, particularly among those with extensive cigarette smoking...
  74. pmc Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial
    Stephen I Rennard
    Pulmonary Critical Care, Allergy and Sleep Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198 5885, USA
    Drugs 69:549-65. 2009
    ....
  75. ncbi Prediction equations for normal and low lung function from the Health Survey for England
    E Falaschetti
    Dept of Epidemiology and Public Health, Royal Free and University College Medical School, London, UK
    Eur Respir J 23:456-63. 2004
    ..The measurements used were the forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) of a sample of 6,053 "healthy" (nonsmokers with no ..
  76. pmc Associations of IL6 polymorphisms with lung function decline and COPD
    J Q He
    UBC James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, St Paul s Hospital, 1081 Burrard Street, Vancouver, BC, Canada
    Thorax 64:698-704. 2009
    ..There is a functional single nucleotide polymorphism (SNP), -174G/C, in the promoter region of IL6. It was hypothesised that IL6 SNPs influence susceptibility for impaired lung function and COPD in smokers...
  77. ncbi Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
    C Verkindre
    Hopital de Bethune, Beuvry, France
    Respir Med 104:1482-9. 2010
    ..All doses of NVA237 and tiotropium were well tolerated. NVA237 once-daily was effective and well tolerated versus placebo, and demonstrated rapid and sustained 24-h bronchodilation. (ClinicalTrials.gov Identifier: NCT00501852)...
  78. ncbi Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis
    Kaïssa de Boer
    The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
    Thorax 66:680-5. 2011
    ..The aim of this study was to determine if frequent pulmonary exacerbations are associated with greater declines in lung function, or an accelerated time to death or lung transplantation in adults with CF...
  79. ncbi Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease
    M Dahl
    Department of Clinical Biochemistry, Herlev and Copenhagen University Hospitals, Copenhagen, Denmark
    Am J Respir Crit Care Med 164:1008-11. 2001
    ..We measured plasma fibrinogen and forced expiratory volume in 1 s (FEV(1)), and assessed prospectively COPD hospitalizations in 8,955 adults from the Danish general ..
  80. ncbi Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial
    Donald P Tashkin
    Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, California, USA
    Drugs 68:1975-2000. 2008
    ..Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patients with COPD...
  81. ncbi Randomized controlled study of in-hospital exercise training programs in children with cystic fibrosis
    H C Selvadurai
    Children s Chest Research Centre and Department of Respiratory Medicine, Royal Alexandra Hospital for Children, New South Wales, Australia
    Pediatr Pulmonol 33:194-200. 2002
    ..A combination of aerobic and resistance training may be the best training program, and future studies to assess optimal training programs for CF patients are indicated...
  82. ncbi Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial
    Thérèse S Lapperre
    Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
    Ann Intern Med 151:517-27. 2009
    ..Inhaled corticosteroids (ICSs) and long-acting beta(2)-agonists (LABAs) are used to treat moderate to severe chronic obstructive pulmonary disease (COPD)...
  83. ncbi Obesity is a risk factor for dyspnea but not for airflow obstruction
    Don D Sin
    Department of Medicine, University of Alberta, Edmonton, Canada T6G 2B7
    Arch Intern Med 162:1477-81. 2002
    ..However, since obesity can cause dyspnea through mechanisms other than airflow obstruction, diagnostic misclassification of asthma could partially account for this association...
  84. pmc Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
    Wendy C Moore
    Center for Human Genomics, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Allergy Clin Immunol 119:405-13. 2007
    ..Severe asthma causes the majority of asthma morbidity. Understanding mechanisms that contribute to the development of severe disease is important...
  85. ncbi Waist circumference is associated with pulmonary function in normal-weight, overweight, and obese subjects
    Yue Chen
    Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada
    Am J Clin Nutr 85:35-9. 2007
    ..Because both weight and height are indicators of body size, body mass index (BMI) may not be an ideal index of obesity in prediction of pulmonary dysfunction...
  86. pmc Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology
    Ravi S Aysola
    Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Chest 134:1183-91. 2008
    ..To prospectively apply an automated, quantitative three-dimensional approach to imaging and airway analysis to assess airway remodeling in asthma patients...
  87. ncbi Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD
    Francois Maltais
    Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Universite Laval, 2725 Chemin Sainte Foy, Quebec G1V 4G5, Canada
    Respir Med 105:580-7. 2011
    ..Static and dynamic lung hyperinflation are associated with exercise impairment and poor outcomes in COPD patients. Aclidinium bromide is a novel, long-acting inhaled muscarinic antagonist currently in development for COPD treatment...
  88. ncbi Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD
    Tom M A Wilkinson
    Academic Unit of Respiratory Medicine, St Bartholomew s and The Royal London School of Medicine, St Bartholomew s Hospital, London, UK
    Chest 129:317-24. 2006
    ....
  89. ncbi Quantitative assessment of emphysema, air trapping, and airway thickening on computed tomography
    Young Kyung Lee
    Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Research Institute of Radiology, 388 1, Pungnap dong, Songpa Ku, Seoul 138 736, Korea
    Lung 186:157-65. 2008
    ..563, p<0.001). MLD(exp) showed the strongest correlation with the BODE index (R= -0.756, p<0.001). We conclude that the severity of emphysema and air trapping measured on CT correlated with the PFT parameters 6MWD and BMI...
  90. ncbi Bronchodilator responsiveness in patients with COPD
    D P Tashkin
    David Geffen School of Medicine, UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90024, USA
    Eur Respir J 31:742-50. 2008
    ..Spirometry was performed before and 90 min following ipratropium administration. The criteria used for forced expiratory volume in one second (FEV(1)) responsiveness were: >or=12% increase over baseline and >or=200 mL; >or=..
  91. pmc Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD
    Jennifer K Quint
    Academic Unit of Respiratory Medicine, University College London, Rowland Hill St, London NW3 2PF, England
    Chest 137:812-22. 2010
    ....
  92. ncbi Dynamic hyperinflation with bronchoconstriction: differences between obese and nonobese women with asthma
    Tim J T Sutherland
    Respiratory Research Unit, Department of Medical and Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
    Am J Respir Crit Care Med 177:970-5. 2008
    ..It is unclear whether the dynamic changes that occur during bronchoconstriction differ between obese versus nonobese patients with asthma...
  93. ncbi Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trøndelag Study
    A Langhammer
    , The Norwegian University of Science and Technology (NTNU, Verdal
    Eur Respir J 18:770-9. 2001
    ..After a plateau in younger adults, the variables declined by age. The reference values for forced expiratory volume in one second and forced vital capacity from the present study, were higher than those given by ..
  94. ncbi Indacaterol once-daily is equally effective dosed in the evening or morning in COPD
    H Magnussen
    Pulmonary Research Institute, Hospital Grosshansdorf, Grosshansdorf, Germany
    Respir Med 104:1869-76. 2010
    ..05); and the % of days able to perform usual activities (by 6.7 and 7.8 points; p < 0.05). Indacaterol provided 24-h bronchodilation and improvement in symptoms regardless of whether taken regularly in the morning or evening...
  95. pmc Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation
    Sue R Downie
    Woolcock Institute of Medical Research, Camperdown, NSW 2050, Australia
    Thorax 62:684-9. 2007
    ....
  96. pmc Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study
    Emily S Wan
    Channing Laboratory and Pulmonary and Critical Care Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Respir Crit Care Med 184:57-63. 2011
    ..These smokers are a poorly characterized group due to their systematic exclusion from chronic obstructive pulmonary disease (COPD) studies...
  97. pmc Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry
    Liam G Heaney
    Centre for Infection and Immunity, Queen s University of Belfast, Level 8, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK
    Thorax 65:787-94. 2010
    ....
  98. ncbi How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?
    Kjetil Herland
    Department of Community Medicine and General Practice, NTNU, Trondheim, Norway
    Respir Med 99:11-9. 2005
    ..It is questionable whether such data can extrapolated to a larger, "real life" population of patients with obstructive lung disease. Moreover, we found surprisingly minor differences between the Specialist and GP populations...
  99. pmc Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica
    John M Brehm
    Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, USA
    Am J Respir Crit Care Med 179:765-71. 2009
    ..Maternal vitamin D intake during pregnancy has been inversely associated with asthma symptoms in early childhood. However, no study has examined the relationship between measured vitamin D levels and markers of asthma severity in childhood...
  100. ncbi Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease
    D E O'Donnell
    Respiratory Investigation Unit, Departments of Medicine, and Community Health and Epidemiology, Queen s University, Kingston, Ontario, Canada
    Am J Respir Crit Care Med 158:1557-65. 1998
    ..35, p < 0.001). We concluded that Borg dyspnea ratings, and measurements of IC and endurance time during submaximal cycle exercise testing are highly reproducible and responsive to change in severe COPD...
  101. ncbi Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma
    Florence N Schleich
    Department of Pulmonary Medicine, CHU Sart Tilman, Liege, I GIGA Research Group, University of Liege, Belgium
    Thorax 65:1039-44. 2010
    ..However, the FeNO threshold value that identifies a sputum eosinophil count ≥3% in an unselected population of patients with asthma has been poorly studied...

Research Grants68

  1. Early Life Conditions, Survival, and Health: A Pedigree-Based Population Study
    Ken R Smith; Fiscal Year: 2013
    ..fasting glucose and insulin resistance, telomere length, blood pressure, heart rate, grip strength, forced expiratory volume (FEV1), and BMI...
  2. Interactions of Diesel Exhaust and Respiratory Viruses in Asthmatic Children
    Toby C Lewis; Fiscal Year: 2013
    ..and PCR-confirmed viral infection on asthma health outcomes (primarily: fluctuations in daily measures of forced expiratory volume in 1 second (FEV1) and frequency of self-reported wheezing)...
  3. Study of Soy Isoflavones in Asthma (SOYA)
    Lewis J Smith; Fiscal Year: 2013
    ..The primary outcome measure is forced expiratory volume in one second (FEV1), an objective measure of lung function...
  4. Study of Soy Isoflavones in Asthma (SOYA)
    Robert A Wise; Fiscal Year: 2013
    ..The primary outcome measure is forced expiratory volume in one second (FEV1), an objective measure of lung function...
  5. Indoor woodsmoke PM and asthma: a randomized trial
    TONY JOHN WARD; Fiscal Year: 2012
    ..outcomes measured prior to and following the intervention will include peak expiratory flow (PEF) and forced expiratory volume in first second (FEV1), biomarkers in exhaled breath condensate (i.e...
  6. Risk factors for site-specific metastasis in esophageal cancer
    JULIAN ABRAMS; Fiscal Year: 2012
    ..Lung damage will be quantified by forced expiratory volume (one second) and by the major urinary prostaglandin-E2 metabolite, an experimental measure of tobacco-..
  7. Developing an Automated Symptom Monitoring Device for Adolescents with Asthma
    Hyekyun Rhee; Fiscal Year: 2012
    ..Data from ADAM will be compared with Forced Expiratory Volume at 1 second, exhaled fractional nitric oxide, and data from questionnaires including the Asthma Control ..
  8. Discovering Pathways of Functional Decline: A GWAS Approach
    Yongmei Liu; Fiscal Year: 2010
    ..total mortality and the onset of mobility limitations: grip strength, usual gait speed, IL-6 levels, and forced expiratory volume in 1s (FEV1)...
  9. Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol in Mild Asthma
    Nicola A Hanania; Fiscal Year: 2013
    ..The primary outcome measure will be the change in airway hyperresponsiveness to methacholine (PC20 forced expiratory volume in one second, FEV1). Secondary outcomes will be measures of lung function (FEV1) and asthma control...
  10. Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648)
    JAY A BARTH; Fiscal Year: 2013
    ..patients will include ~208 patients with nonsense-mutation-mediated CF who are e6 years of age and have a forced expiratory volume in 1 second (FEV1) e40% and d90% of predicted...
  11. PHARMACOGENOMICS OF INHALED CORTICOSTEROID RESPONSIVENESS IN PATIENTS WITH ASTHMA
    Keoki Williams; Fiscal Year: 2013
    ..in ICS response with only 33 per cent to 50 per cent of patients demonstrating substantial improvement in forced expiratory volume in 1 second (FEV1) following therapy...
  12. Early Intervention in Pulmonary Exacerbation in CF
    Noah Lechtzin; Fiscal Year: 2013
    ..will be compared to usual care with the primary outcome measure being lung function as measured with forced expiratory volume in the first second (FEV1)...
  13. Redox disturbances and corticosteroid responses in children with severe asthma
    ANNE MENTRO FITZPATRICK; Fiscal Year: 2013
    ..Corticosteroid insensitivity will be defined as <15% improvement in the forced expiratory volume in one second 4 weeks after triamcinolone administration...
  14. "Biomarker signature in COPD"
    Yohannes Tesfaigzi; Fiscal Year: 2012
    ..smoking and pulmonary function is well-established, there is considerable variability in the reduction in forced expiratory volume in one second or FEVi among smokers with similar smoking exposures...
  15. Health Effects of CREON2000 In Asthmatic Children
    Mark Glazman; Fiscal Year: 2003
    ..indoor allergen) and airway limitation by objective pulmonary function testing (a 12-15% change in forced expiratory volume in one second (FEV-1)...
  16. Supplemental Se and Vitamin E and Pulmonary Function
    PATRICIA CASSANO; Fiscal Year: 2007
    ..The primary outcome will be change between baseline and year 3 in forced expiratory volume in the first second (FEV1)...
  17. Testing a Measurement Model of Acute Dyspnea
    Mark Parshall; Fiscal Year: 2005
    ..asked to complete a daily dyspnea questionnaire and perform bedside pyrometer (forced vital capacity and forced expiratory volume in the 1st sec) on three consecutive days; b-type natriuretic peptide (BNP) will be analyzed at study ..
  18. PHASE III TRIAL FO SIROLIMUS IN LYMPHANGIOLEIOMYLMATOSIS
    Francis McCormack; Fiscal Year: 2009
    ..The primary outcome will be change in forced expiratory volume in one second (FEV1) slope over twelve months...
  19. SULFUR OXIDES EFFECTS ON LUNG FUNCTION IN ASTHMATICS
    Jane Koenig; Fiscal Year: 1991
    ..In all studies the primary pulmonary functions to be assessed will be forced expiratory volume in one second (FEV1), total respiratory resistance and maximal flow...
  20. School Environmental Exposures and Measures of the Asthmatic Disease Process
    ELANOR SIDMAN; Fiscal Year: 2007
    ..The children will be asked to provide exhaled breath samples and forced expiratory volume in 1 second (FEV1) measurements during a home visit and then twice during a single school visit...
  21. A RANDOMIZED TRIAL TO REDUCE ETS IN CHILDREN WITH ASTHMA
    Bruce Lanphear; Fiscal Year: 2003
    ..reduction group will have improvement in pulmonary function as measured by >10 percent difference in forced expiratory volume at 1 second (FEV 1) and >15 percent difference in forced expiratory fraction of 25 percent-75 percent (..
  22. PREDICTORS OF QUALITY OF LIFE: LUNG TRANSPLANT PATIENTS
    Dorothy Lanuza; Fiscal Year: 2004
    ..g., forced expiratory volume in 1 second [FEV1], blood pressure [BP], heart rate [HR]); 2) distance walked in 6-minute walk test; 3) ..
  23. Health Effects of CREON2000 In Asthmatic Children
    Mark Glazman; Fiscal Year: 2009
    ..was found to significantly improve pulmonary function (reduced Peak Flow variability (PEFRvar), increase Forced Expiratory Volume in 1 second (FEV1), and to reduce asthma medication use and symptom severity (shortness of breath, chest ..
  24. Phase 2 study of VX-770 in Cystic Fibrosis Subjectswith G551D
    CLAUDIA ORDONEZ; Fiscal Year: 2007
    ..Secondary endpoints will be nasal potential difference (NPD), sweat chloride, forced expiratory volume in 1 second (FEV1), and pharmacokinetic parameters...
  25. Family Based Analysis of Modifiers of CF Lung Disease
    Hara Levy; Fiscal Year: 2007
    ..factors that account for the variability in expression of CF lung disease as measured by lung function, forced expiratory volume in one second (FEV1), in patients with the delta 508 genotype...
  26. NATIONAL COOPERATIVE INNER-CITY ASTHMA STUDY
    James Stout; Fiscal Year: 2001
    ..be assessed according to the following four domains: (1) physiologic measures (methacholine challenge, forced expiratory volume in one second (FEV-1), peak expiratory flow rate; (2) health care use (asthma hospitalizations and acute ..
  27. Nutritional influences on lung function
    PATRICIA CASSANO; Fiscal Year: 2002
    ..1987) will be examined in relation to pulmonary outcomes over the subsequent 13-year period, including forced expiratory volume in the first second (FEV1), methacholine airways responsiveness, and incident COPD...
  28. IMPROVING CHRONIC DISEASE HEALTH STATUS AND UTILIZATION
    Jan Wallander; Fiscal Year: 2000
    ..Health status is assessed by forced expiratory volume and body mass index at 3 months post-intervention...
  29. LUNG HEALTH STUDY--LONG TERM FOLLOW UP
    Donald Tashkin; Fiscal Year: 2002
    ..All ten of the original LHS clinical centers plan to participate in this study. To minimize bias, all surviving participants of the LHS will be invited to participate, giving a potential sample size of 5600. ..
  30. SCLERODERMA LUNG STUDY
    Donald Tashkin; Fiscal Year: 2003
    ..abstract_text> ..
  31. Distal Lung Inflammation Effect on Asthma Exacerbations
    Donald Tashkin; Fiscal Year: 2008
    ..This study has the potential to clarify the contribution of the "silent zone" to the persistent morbidity encountered with asthma. ..
  32. Response to Beta2-Agonists in Acute Severe Asthma
    Nicola Hanania; Fiscal Year: 2008
    ..The response to beta2-agonists in acute asthma is traditionally determined by the change in the forced expiratory volume in the first second (FEV1,) measured using a forced expiratory maneuver preceded by deep inhalation (DI)...
  33. Assessment and prediction of costs and adverse health outcomes in COPD
    Theodore Omachi; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  34. MECHANISMS OF RHINOVIRUS INDUCED ASTHMA
    William Busse; Fiscal Year: 2002
    ..The proposed studies will provide new evidence as the mechanisms by which RV-infected epithelial cells cause granulocytic bronchial inflammation and asthma exacerbations. ..
  35. Severe Asthma From Respiratory Infections
    William W Busse; Fiscal Year: 2010
    ..These studies will provide new insights into the mechanisms of asthma, particularly severe disease, and possibilities of new approaches to treatment. ..
  36. Fish Oil Intake, Biomarkers and Change in Lung Function
    R Barr; Fiscal Year: 2008
    ..Use of this existing cohort with previously collected blood samples will provide relatively cost-effective results about this potentially promising and safe therapy for COPD. ..
  37. Serum Inflammatory Biomarkers as Predictors of COPD Morbidity and Morality
    Stefano Guerra; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  38. Asthma Candidate Genes in Alpha 1-Antitrypsin Deficiency
    Dawn DeMeo; Fiscal Year: 2007
    ..The identification of modifying factors of COPD in AAT deficiency may have significant public health relevance to COPD patients without AAT deficiency. ..
  39. Genetic Determinants of COPD in Diverse Ethnic Groups
    Edwin K Silverman; Fiscal Year: 2010
    ..The overall goal of this proposal is to test the hypothesis that shared genetic determinants influence the development of COPD in diverse ethnic groups. ..
  40. Genetic Modifiers of Alpha 1-Antitrypsin Deficiency
    Edwin Silverman; Fiscal Year: 2005
    ....
  41. Genetics of COPD in NETT
    Edwin Silverman; Fiscal Year: 2005
    ..abstract_text> ..
  42. APPROACHES TO THE GENETICS OF COPD
    Edwin Silverman; Fiscal Year: 2003
    ..abstract_text> ..
  43. Obesity, Inflammation and Response to Therapy in Asthma
    EVERETT RAND SUTHERLAND; Fiscal Year: 2010
    ..End of Abstract) ..
  44. Towards a better understanding of work-aggravated asthma
    Catherine Lemiere; Fiscal Year: 2009
    ..The occurrence of asthma exacerbations will be recorded. The economic impact of WAA will be assessed in terms of work disability and use of health resources and compared with OA and asthma without OA not WAA. ..
  45. Socioeconomic Status, Stress & Asthma Biological Markers
    Edith Chen; Fiscal Year: 2009
    ..The results from this project will allow us to begin developing models of how the larger social environment comes to affect a child's clinical course of asthma. ..
  46. NASD Academic ED Collaborative - UC San Diego
    Theodore Chan; Fiscal Year: 2004
    ..UCSD ED investigators will be responsible for following up on difficult to reach) patients. Local data and survey results will be submitted to the R-25 and R-21 sites for analysis. ..
  47. SCLERODERMA LUNG STUDY
    Robert Wise; Fiscal Year: 2003
    ..abstract_text> ..
  48. The Placebo Effect in Asthma
    Robert Wise; Fiscal Year: 2005
    ..Understanding the placebo response can lead to improvements in research and treatment of asthma. ..
  49. Genetic epidemiology of TLR4 alleles and bacteremia
    Jason Chien; Fiscal Year: 2006
    ..Ultimately, this cohort of patients will be developed in anticipation of future genetic discoveries in the complicated pathway of pathogen recognition and host inflammatory response. ..
  50. Clinical Trial of Acid Reflux Therapy in Asthma
    Robert Wise; Fiscal Year: 2007
    ..Pre-specified subgroup analyses will be conducted to determine if there are clinical or demographic characteristics that predict benefit from treatment of GERD in asthma. ..
  51. Biomarkers of oxidative stress and inflammation in COPD
    William MacNee; Fiscal Year: 2005
    ..Such information will allow the identification of novel biomarkers and the fingerprints themselves may represent a mechanism to stratify COPD patients and allow the assessment of novel therapies. ..
  52. CARE Network--St. Louis Center
    Robert Strunk; Fiscal Year: 2008
    ..End of abstract.) [unreadable] [unreadable]..
  53. TGF-BETA AND MATRIX METALLOPROTEINASES IN AIRWAY REPAIR
    Sally Wenzel; Fiscal Year: 2002
    ..abstract_text> ..
  54. Rhinosinusitis in Asthma
    ANNE DIXON; Fiscal Year: 2008
    ..At the same time it will advance our understanding of the link between the upper and lower airway in asthma and the results of these studies will guide physicians caring for asthmatic patients. ..
  55. ASTHMA HEALTH OUTCOMES FOLLOWING INTENSIVE CARE
    Mark Eisner; Fiscal Year: 2004
    ..This award will enable Dr. Eisner's continued progression to an independent clinical investigator. ..
  56. ASTHMA AND INTERVENTIONS IN THE EMERGENCY DEPARTMENT
    Robert Strunk; Fiscal Year: 2002
    ..The intent to treat model will be used, as primary outcome can be obtained after consent even if not contact cannot be made at 2 week and 6 month phone calls. ..
  57. Socioeconomics Status&Respiratory/Cardiovascular Health
    Edith Chen; Fiscal Year: 2003
    ..These analyses could have implications for how to time interventions to reduce health disparities in children, and for understanding the mediators that drive the relationship between SES and childhood health. ..
  58. Th2 effects on eicosanoid pathways: implications for altered innate responses in
    Sally E Wenzel; Fiscal Year: 2010
    ..These three aims should provide new insights into how relationships between innate and adaptive/allergic immune responses influence inflammatory/repair, and finally clinical outcomes in chronic and acute asthma. ..
  59. Inflammation of Myofibroblasts and Loss of Elastic Recoil in Severe Asthma
    Sally E Wenzel; Fiscal Year: 2010
    ..Completing these aims should lead to an improved understanding of the contribution of inflammation and injury repair in the small airways/alveoli to the development of severe asthma. These findings may improve therapy as well. ..
  60. Epidemiology of Regulatory T Cells in Pregnancy and Childhood Atopic Diseases
    Ganesa Wegienka; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  61. Disability and Health Outcomes in COPD
    Mark Eisner; Fiscal Year: 2008
    ..Based on this work, intervention strategies can be designed that target reduction of functional limitation and disability to improve downstream health outcomes. ..
  62. ALTERED MATRIX METALLOPROTEINASES IN HEART FAILURE
    JEANINE D ARMIENTO; Fiscal Year: 2002
    ..Finally, this proposal will investigate the role of interstitial collagenase (MMP-13) in cardiac function and development through the generation of an MMP-13 knockout mouse. ..
  63. ADENOVIRAL INFECTION IN THE PATHOGENESIS OF EMPHYSEMA
    James Hogg; Fiscal Year: 2003
    ..The information gathered from these studies will provide new insights into the pathogenesis of emphysema and help explain why some smokers develop emphysema and others do not. ..
  64. Novel, Noninvasive Biomarker of Fruit & Vegetable Intake
    Susan Mayne; Fiscal Year: 2005
    ..abstract_text> ..
  65. ASTHMA CLINICAL RESEARCH NETWORK
    ROBERT LEMANSKE; Fiscal Year: 2002
    ....
  66. RETINAL ARTERIOLAR ABNORMALITIES AND CV MORTALITY
    Ronald Klein; Fiscal Year: 2002
    ..Data from this study will improve the understanding of the association between microvascular characteristics and cardiovascular mortality. ..
  67. Prospective Study of Diet, Physical Activity, BMI and Risk of Pulmonary Embolism
    Carlos Camargo; Fiscal Year: 2008
    ..We believe that quantifying these modifiable risk factors will lead to public health interventions that decrease the incidence of pulmonary embolism in the elderly population. [unreadable] [unreadable] [unreadable]..